Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (4566)	2/3/2005 8:34:12 AM
From: Walkingshadow	Read Replies (1) \| Respond to of 8752

Yes, QQQQ looks like it is really starting to struggle here, and I agree we might not see that overhead gap fill. Besides the hammer you pointed out, we have now seen 3 narrow-range days in a row, together consistent with reversal here to the downside. There is an slim chance $38 might get hit on an intraday basis, but a close at or above $38 is now looking increasingly unlikely as you say. 139.142.147.22 AMZN's miss last night will not help the bulls today, and will bring down the sector. This morning, the analysts are stomping all over AMZN. T

To: Vendit™ who wrote (4566)	2/3/2005 9:37:51 AM
From: Walkingshadow	Respond to of 8752

ALNY yesterday was boosted by an upgrade. ============================================== Alnylam Pharmaceuticals upgraded to Buy at BofA; tgt $9.50 (ALNY) 7.00 : Banc of America upgrades ALNY to Buy from Neutral with a $9.50 tgt. Firm believes the co is a leader in the rapidly-developing field of RNAi-based therapies, and that RNAi could be the next great therapeutic platform, transforming the pharmaceutical industry. They believe 2005 will be a catalyst-rich year, with multiple new programs announced and business development goals accomplished. ============================================== They have a strategic alliance now with MRK, which should provide them with the muscle needed for clinical trials and marketing. We'll see increasing news on this one over the next year or two, they are ahead of the pack in RNA interference. They have plans to conduct clinical trials related to respiratory syncitial virus and spinal cord injury, but there are many, many possible clinical applications of the technology. As I posted before, I don't often buy a good story. That said, I think you could make a good case for a long-term position, and a better case for repetitive trading. I think this one will eventually attract the mo-mo crowd, and the stock is driven by news (we'll see plenty of that this year). The float is 11 million shares with 45% held by insiders, and currently the stock is trading at $7.35. That means the remaining 6 million shares would require less than $40 million. Since the average daily volume is less than 200,000, the stock could be easily moved with just a few hundred thousand shares. The technology is exotic and not well understood by the street. The only thing missing from the mo-mo equation are shorts---less than 2% of the float is held short. And, right now the stock is extremely oversold and coming off support, with buy signals in place: 139.142.147.218 T